Medtronic plc, a global leader in healthcare technology, has announced a significant milestone in the regulatory review process for its INFUSE™ Bone Graft for Transforaminal Lumbar Interbody Fusion $(TLIF)$ procedure. Following a successful interim analysis, the independent Data Monitoring Committee recommended stopping further enrollment in the ongoing randomized controlled trial, citing early success. Medtronic is now preparing a Premarket Approval (PMA) submission to the U.S. Food and Drug Administration (FDA) to continue advancing this innovative spine surgery technology. Additionally, the company plans to apply for a New Technology Add-on Payment $(NTAP)$ with the U.S. Centers for Medicare & Medicaid Services, aiming to enhance the economic value of this innovation. This progress underscores Medtronic's commitment to bringing transformative technology to patients efficiently and responsibly.